PPARG and breast cancer: This suggestion is supported by the findings that the anticancer effects of combined treatment of γ-tocotrienol with PPARγ antagonists are observed in PPARγ-negative +SA mammary tumor cells, as well as PPARγ silenced (siRNA transfected) PPARγ positive MCF-7 and MDA-MB-231 breast cancer cells.